Last reviewed · How we verify
[11C]raclopride
[11C]raclopride is a radioactive dopamine D2/D3 receptor antagonist used as a positron emission tomography (PET) imaging agent to visualize dopamine receptor binding in the brain.
[11C]raclopride is a radioactive dopamine D2/D3 receptor antagonist used as a positron emission tomography (PET) imaging agent to visualize dopamine receptor binding in the brain. Used for PET imaging of dopamine D2/D3 receptor binding in the brain for research and diagnostic purposes, Assessment of dopaminergic dysfunction in Parkinson's disease, schizophrenia, and other neuropsychiatric disorders.
At a glance
| Generic name | [11C]raclopride |
|---|---|
| Also known as | Raclopride, serial number 009 |
| Sponsor | New York State Psychiatric Institute |
| Drug class | Dopamine D2/D3 receptor antagonist (PET imaging agent) |
| Target | Dopamine D2 receptor, Dopamine D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry, Medical Imaging |
| Phase | FDA-approved |
Mechanism of action
[11C]raclopride is a carbon-11 labeled derivative of raclopride, a selective dopamine D2/D3 receptor antagonist. The radioactive carbon-11 isotope allows real-time visualization of dopamine receptor density and occupancy in vivo using PET imaging. It is primarily used as a research and diagnostic tool to assess dopaminergic neurotransmission in neuropsychiatric and neurodegenerative disorders.
Approved indications
- PET imaging of dopamine D2/D3 receptor binding in the brain for research and diagnostic purposes
- Assessment of dopaminergic dysfunction in Parkinson's disease, schizophrenia, and other neuropsychiatric disorders
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [11C]raclopride CI brief — competitive landscape report
- [11C]raclopride updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI